Curated News
By: NewsRamp Editorial Staff
July 18, 2025
DoD Funds AREVA & SeaStar Medical to Revolutionize Burn and Injury Treatments
TLDR
- SeaStar Medical's SCD therapy, backed by a $2 million DoD grant, offers a groundbreaking advantage in treating severe burns and infections by reducing hyperinflammation and improving survival rates.
- The SCD therapy works by modifying the immune response outside the body, neutralizing overactive immune cells to reduce hyperinflammation, then reintroducing them in a less active state.
- This innovative therapy promises to make tomorrow better by potentially saving lives and reducing the need for lifelong dialysis in patients with severe trauma and infections.
- SeaStar Medical's device, already cutting pediatric AKI mortality rates by half, now explores treating severe burns, showcasing its broad potential in acute and chronic diseases.
Impact - Why it Matters
This news is crucial as it highlights a significant advancement in medical treatment for severe burns and injuries, which can lead to life-threatening conditions like organ failure. The development of SeaStar Medical’s SCD therapy offers a beacon of hope for both military and civilian patients, potentially reducing mortality rates and the need for lifelong dialysis. Its success could pave the way for broader applications in treating various acute and chronic diseases, marking a monumental leap forward in medical science and patient care.
Summary
In a groundbreaking development for medical science, the Autonomous Reanimation and Evacuation (AREVA) Research Institute has been awarded a significant grant by the United States Department of Defense (DoD) to explore innovative treatments for severe burns, inhalation injuries, and septicemia. This research will focus on SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy, a novel approach aimed at reducing destructive hyperinflammation by modifying the body's immune response. The study, supported by over $2 million in funding, represents a pivotal step towards improving survival rates and recovery outcomes for both military personnel and civilians suffering from severe trauma and infection.
The collaboration between AREVA and SeaStar Medical, with operational support from The Geneva Foundation, underscores the potential of SCD therapy to revolutionize care for critically injured patients. Already proven effective in treating pediatric acute kidney injury, the SCD therapy's application could extend to a wide range of acute and chronic conditions, offering hope to patients with limited treatment options. This initiative not only highlights the DoD's confidence in AREVA's research capabilities but also in the transformative potential of SeaStar's technology to save lives and improve patient care.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, DoD Funds AREVA & SeaStar Medical to Revolutionize Burn and Injury Treatments
